Compare Eli Lilly And Co (LLY) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Prospect Capital Corporation — how do they compare? Eli Lilly And Co trades at $1,214 (market cap $1.08T), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Eli Lilly And Co is far larger — about 947.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.93%). Which is the better fit depends on your goals.
| LLY | PSEC | |
|---|---|---|
Market Cap | $1.08T | $1.14B |
Sector | Health | Financials |
52-Week High | $1.24K | $3.05 |
52-Week Low | $639.43 | $2.11 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | 21.93% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
